The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 04, 2025
Filed:
Sep. 03, 2020
Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;
Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;
Université DE Lille, Lille, FR;
Institut Pasteur DE Lille, Lille, FR;
Université DE Montpellier, Montpellier, FR;
Institut Régional Du Cancer DE Montpellier, Montpellier, FR;
Philippe Gosset, Lille, FR;
Muriel Pichavant, Lille, FR;
Pierre Martineau, Montpellier, FR;
Myriam Chentouf, Montpellier, FR;
Bruno Robert, Montpellier, FR;
Mélina Le Roux, Tourcoing, FR;
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris, FR;
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris, FR;
UNIVERSITE DE LILLE, Paris, FR;
INSTITUT PASTEUR DE LILLE, Lille, FR;
UNIVERSITE DE MONTPELLIER, Montpellier, FR;
INSTITUT REGIONAL DU CANCER DE MONTPELLIER, Montpellier, FR;
Abstract
Chronic obstructive pulmonary disease (COPD) remains a major cause of morbidity and mortality worldwide. Acute exacerbation of COPD (AE-COPD) in patients are mostly due to respiratory infection and are associated with an inexorable decline in lung function, enhanced oedema as well as airway and systemic inflammation. Previous results show that treatment with anti-IL-20Rb blocking antibodies increased the bacterial clearance in control mice infected byand protected CS-exposed mice from bacterial infection, by decreasing the bacterial burden and the inflammatory infiltrate. Therefore there is an interest for generating monoclonal antibodies specific for IL-20Rb with a neutralizing activity for their use in the treatment of AE-COPD. The present invention fulfills this need by providing antibodies having specificity for IL-20Rb.